Schrodinger Inc
NASDAQ:SDGR
Schrodinger Inc
In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry.
Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.
In the bustling realm of computational chemistry, Schrödinger Inc. has carved a unique niche, transforming the way pharmaceutical and biotechnology companies approach drug discovery. Founded in 1990, the company has become synonymous with innovation, leveraging powerful physics-based software platforms that simulate molecular interactions at an atomic level. By providing researchers with tools to predict the behavior of complex biological systems, Schrödinger effectively bridges the gap between traditional experimental methods and cutting-edge computational techniques. Their flagship product, the Schrödinger platform, is instrumental in accelerating the drug discovery process, allowing scientists to virtually test countless compounds before selecting the most promising candidates for laboratory synthesis and testing. This capability significantly reduces the time and cost involved in bringing new drugs to market, providing tremendous value to its clients in the pharmaceutical industry.
Schrödinger's financial success stems from its diversified business model, which includes software licensing, collaborative research and development projects, and, interestingly, strategic investments in biotech firms. The company licenses its software to a broad range of industries, from pharmaceuticals to materials science, generating a steady stream of revenue. Meanwhile, their collaborative projects enable Schrödinger to participate in revenue sharing or milestone payments based on the compounds developed using their technology. Additionally, by investing in biotech companies utilizing their software, Schrödinger not only fosters innovation but also stands to gain financially from any commercial success. This multifaceted approach not only secures their leadership in the industry but also ensures a robust growth trajectory, as they continue to expand the horizons of computational science.
Strong 2025 Growth: Schrodinger delivered 23% total revenue growth in 2025, reaching $256 million with continued strength in both software and drug discovery businesses.
Software Business: Software revenue reached $199.5 million with 11% growth, driven by increased hosted and maintenance revenue; software ACV grew to $198.5 million.
Transition to Hosted: Company is accelerating a transition to hosted (cloud-based) contracts, aiming to have 75% hosted software revenue by 2028, impacting near-term revenue recognition.
Expense Discipline: Operating expenses fell by about 9%, reflecting cost reduction initiatives while still investing in long-term software growth.
2026 Guidance: Management expects ACV of $218 million to $228 million (10% to 15% growth) and $55 million to $65 million in drug discovery revenue, focusing guidance on ACV due to revenue timing shifts from the hosted transition.
Profitability Target: Company is targeting positive adjusted EBITDA by the end of 2028, supported by a strong $402 million cash position.
Therapeutics Pipeline: Multiple partnered and internal clinical programs are progressing, with up to $5 billion in potential milestones and growing royalty opportunities.
